Immunogenicity and safety of IXIARO (IC51) in a Phase II study in healthy Indian children between 1 and 3 years of age. (Q43756658)

26 November 2017

Immunogenicity and safety of IXIARO (IC51) in a Phase II study in healthy Indian children between 1 and 3 years of age. (English)

1 reference

26 November 2017

0 references

A Kaltenböck

1

1 reference

26 November 2017

K Dubischar-Kastner

2

1 reference

26 November 2017

E Schuller

3

1 reference

26 November 2017

Mahima Datla

4

1 reference

26 November 2017

C S Klade

5

1 reference

26 November 2017

T S A Kishore

6

1 reference

26 November 2017

language of work or name

English

0 references

publication date

24 October 2009

1 reference

26 November 2017

6

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

26 November 2017

28

1 reference

26 November 2017

834-839

1 reference

26 November 2017

3

1 reference

The epidemiology of Japanese encephalitis: prospects for prevention

26 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.024

Japanese encephalitis vaccine for travelers: exploring the limits of risk.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.024

Randomized, double-blind, placebo-controlled phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.024

Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.024

Japanese encephalitis in a Finnish traveler on a two-week holiday in Thailand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.024

Fatal Japanese encephalitis in a Danish tourist visiting Bali for 12 days

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.024

Japanese encephalitis after a 10-day holiday in Bali

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.024

Assay of arbovirus neutralizing antibody by micro methods

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.024

Japanese encephalitis vaccination in HIV-infected children with immune recovery after highly active antiretroviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.024

Past, Present, and Future of Japanese Encephalitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.024

A decade of Japanese encephalitis surveillance in Sarawak, Malaysia: 1997-2006.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.024

Systemic immediate-type reactions to gelatin included in Japanese encephalitis vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.024

IgE sensitization to gelatin: the probable role of gelatin-containing diphtheria-tetanus-acellular pertussis (DTaP) vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.024

Neurological complications and Japanese encephalitis vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.024

Allergic reactions to Japanese encephalitis vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.024

Long-term immunogenicity of the new Vero cell-derived, inactivated Japanese encephalitis virus vaccine IC51 Six and 12 month results of a multicenter follow-up phase 3 study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.024

Safety and immunogenicity of concomitant vaccination with the cell-culture based Japanese Encephalitis vaccine IC51 and the hepatitis A vaccine HAVRIX1440 in healthy subjects: A single-blind, randomized, controlled Phase 3 study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.024

Effect of pre-existing anti-tick-borne encephalitis virus immunity on neutralising antibody response to the Vero cell-derived, inactivated Japanese encephalitis virus vaccine candidate IC51.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.024

10.1016/J.VACCINE.2009.10.024

7 January 2021

Identifiers

DOI

1 reference

26 November 2017

1 reference